Document:

EX-10.11

 Exhibit 10.11 

TOBIRA THERAPEUTICS, INC. 

198 US HIGHWAY 9 NORTH, SUITE 200 

MANALAPAN, NJ 07726 
 July 23,
2011 
 Helen Jenkins 
 Dear Helen, 

Tobira Therapeutics, Inc. (the “Company”) is pleased to offer you employment on the following terms: 

1. Position. Your initial title will be Senior Vice President, Program Leadership, and you will initially report to the Company’s
President & CEO. In this capacity, you will perform such tasks as reasonably assigned by the Company’s President & CEO, including but not limited to management of Tobira’s Project Team for clinical development and
commercialization of Cenicriviroc. Your services will be performed partially at the Company’s headquarters in Manalapan, New Jersey, in addition to at the Company’s office in South San Francisco, California. This is a full-time position.
While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company. By signing this letter
agreement, you confirm to the Company that you have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company. 

2. Cash Compensation. The Company will pay you a starting base salary at the rate of $215,000 per year, payable in accordance with the
Company’s standard payroll schedule. This salary will be subject to adjustment pursuant to the Company’s employee compensation policies in effect from time to time. In addition, you will be eligible to be considered for an incentive bonus
for each fiscal year of the Company. The bonus (if any) will be awarded based on objective or subjective criteria established by the Company’s President & CEO and approved by the Company’s Board of Directors. Your target bonus
will be equal to 20% of your annual base salary. Any bonus for the 2011 fiscal year will be pro-rated for the full-year of 2011 based on your start date. The determinations of the Company’s Board of Directors with respect to your bonus will be
final and binding. 
 3. Employee Benefits. As a regular employee of the Company, you will be eligible to participate in a number of
Company-sponsored fringe benefits. In addition, you will be entitled to paid time off in accordance with the Company’s paid time off policy, as in effect from time to time. Such policy currently provides for fifteen (15) days paid vacation
each year, accruing on a monthly basis; two (2) personal days; and a minimum of eight (8) holidays. Please see the Benefits at a Glance Summary, attached hereto as Exhibit A, for more information. 

 Helen Jenkins 

July 22, 2011 
  Page
 2
 
  

 4. Stock Options. Subject to the approval of the Company’s Board of Directors or
its Compensation Committee, promptly following the date on which you commence employment with the Company, you will be granted an option to purchase 0.45% of the fully-diluted shares outstanding as of July 22, 2011 of the Company’s Common
Stock. The exercise price per share of the Option will be determined by the Board of Directors or the Compensation Committee when the Option is granted. The Option will be subject to the terms and conditions applicable to options granted under the
Company’s 2010 Stock Plan (the “Plan”), as described in the Plan and the applicable Stock Option Agreement. The Option will be immediately exercisable, but in the event that your service terminates for any reason before you vest in
the shares, the unvested portion of the purchased shares will be subject to repurchase by the Company at the lower of (a) the original exercise price or (b) the fair market value of the shares at the time your service terminates. You will
vest in 25% of the Option shares after 12 months of continuous service, and the balance will vest in equal monthly installments over the next 36 months of continuous service, as described in the applicable Stock Option Agreement. 

5. Patent, Copyright and Non-Disclosure Agreement. Like all Company employees, you will be required, as a condition of your employment
with the Company, to sign the Company’s standard Patent, Copyright and Non-Disclosure Agreement, a copy of which is attached hereto as Exhibit B. You represent and warrant to the Company that you are under no obligations or commitments,
whether contractual or otherwise, that are inconsistent with your obligations under this Agreement. You represent and warrant that you will not use or disclose, in connection with your Employment, any trade secrets or other proprietary information
or intellectual property in which you or any other person has any right, title or interest and that your employment will not infringe or violate the rights of any other person. You represent and warrant to the Company that you have returned all
property and confidential information belonging to any prior employer. 
 6. Employment Relationship. Employment with the Company is
for no specific period of time. Your employment with the Company will be “at will,” meaning that either you or the Company may terminate your employment at any time and for any reason, with or without cause. Any contrary representations
that may have been made to you are superseded by this letter agreement. This is the full and complete agreement between you and the Company on this term. Although your job duties, title, compensation and benefits, as well as the Company’s
personnel policies and procedures, may change from time to time, the “at will” nature of your employment may only be changed in an express written agreement signed by you and a duly authorized officer of the Company (other than you). 

7. Business Expenses. The Company will reimburse you for all reasonable and necessary out-of-pocket expenses incurred in connection
with your duties to the Company during your employment with the Company. Such reimbursements will be contingent upon your presentation of an itemized account and appropriate supporting documentation, all in accordance with the Company’s
generally applicable policies. Any reimbursement will (a) be paid promptly but not later than the last day of the calendar year following the year in which the expense was incurred, (b) not be affected by any other expenses that are eligible
for reimbursement in any calendar year and (c) not be subject to liquidation or exchange for another benefit. 

  

 Helen Jenkins 

July 22, 2011 
  Page
 3
 
  

 8. Tax Matters. All forms of compensation referred to in this letter agreement
are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You are encouraged to obtain your own tax advice regarding your compensation from the Company. You agree that the Company does not
have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or its Board of Directors related to tax liabilities arising from your compensation. 

9. Interpretation, Amendment and Enforcement. This letter agreement and Exhibits A and B constitute the complete agreement
between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. This letter agreement may
not be amended or modified, except by an express written agreement signed by both you and a duly authorized officer of the Company. The terms of this letter agreement and the resolution of any disputes as to the meaning, effect, performance or
validity of this letter agreement or arising out of, related to, or in any way connected with, this letter agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”) will be governed
by New Jersey law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in New Jersey in connection with any Dispute or any claim related to
any Dispute. 
 * * * * * 

  

 Helen Jenkins 

July 22, 2011 
  Page
 4
 
  

 We hope that you will accept our offer to join the Company, and we are looking forward to
your contributions to the Company’s success. You may indicate your agreement with these terms and accept this offer by signing and dating both the enclosed duplicate original of this letter agreement and the enclosed Patent, Copyright and
Non-Disclosure Agreement and returning them to me. This offer, if not accepted, will expire at the close of business on July 25, 2011. As required by law, your employment with the Company is contingent upon your providing legal proof of your
identity and authorization to work in the United States. Your employment is also contingent upon your starting work with the Company on or before August 3, 2011. 

If you have any questions, please call me at
                    . 
  

			
	Sincerely,
	
	TOBIRA THERAPEUTICS, INC.
		
		 	/s/ Andrew Asa Hindman
	By:	 	Andrew Asa Hindman
	Title:	 	President & Chief Executive Officer

  

			
	I have read and accept this employment offer:
		
		 	/s/ Helen Jenkins
		 	Signature of Employee
		
	Dated:	 	July 23, 2011

 Attachments 
 Exhibit A:
Benefits at a Glance 
 Exhibit B: Patent, Copyright and Non-Disclosure AgreementEX-10.12

 Exhibit 10.12 

TOBIRA THERAPEUTICS, INC. 

April 29, 2014 
 Helen Jenkins 

Dear Helen: 
 You and Tobira Therapeutics, Inc.
(the “Company”) entered into an employment offer letter dated July 23, 2011 (the “Employment Letter”) and a Notice of Stock Option Grant and Stock Option Agreement dated September 29, 2011 (the “Option
Agreement”). The Company would like to amend the Employment Letter and Option Agreement as set forth herein. 
 By signing this letter
and returning it to the Company, you and the Company agree that if the Company is subject to a Change in Control before your Service terminates, then 100% of the then-unvested portion of the shares granted pursuant to the Option Agreement shall
become exercisable. For the purposes hereof: 
 “Change in Control” shall mean (i) the acquisition of the
Company by another entity by means of any transaction or series of related transaction (including, without limitation, any reorganization, merger, stock purchase or consolidation) or (ii) a sale of all or substantially all of the assets of the
Company; unless the Company’s stockholders of record as constituted immediately prior to any such transaction will, immediately after such transaction (by virtue of securities issued as consideration for the Company’s capital stock, assets
or otherwise) hold more than 50% of the voting power of the surviving or acquiring entity. 
 In addition, by signing this letter and
returning it to the Company, you and the Company agree to the following additions to the Employment Letter: 
 5. Severance
Benefits. 
 (a) General. If you are subject to an Involuntary Termination then you will be entitled to the
benefits described in this Section 5. However, this Section 5 will not apply unless you have (i) returned all Company property in your possession and (ii) executed a general release, including a release of all claims that you may
have against the Company or persons affiliated with the Company. The release must be in substantially the form attached hereto as Exhibit A, without alterations. You must execute and return the release on or before the date specified by the
Company in the prescribed form (the “Release Deadline”). The Release Deadline will in no event be later than fifty (50) days after your Separation. If you fail to return the release on or before the Release Deadline, or if you revoke
the release, then you will not be entitled to the benefits described in this Section 5. 

 (b) Salary Continuation. If you are subject to an Involuntary Termination, then the
Company will continue to pay your base salary for a period of six (6) months after your Separation. Your base salary will be paid at the rate in effect at the time of your Separation and in accordance with the Company’s standard payroll
procedures. The salary continuation payments will commence within sixty (60) days after your Separation and, once they commence, will include any unpaid amounts accrued from the date of your Separation. However, if the sixty-day period
described in the preceding sentence spans two calendar years, then the payments will in any event begin in the second calendar year. Notwithstanding the foregoing, if you are subject to an Involuntary Termination in connection with or following a
Change in Control of the Company, then the Company will make a lump sum payment to you equal to one year’s base salary at the rate in effect at the time of your Separation, subject to all applicable withholding taxes. 

(c) COBRA. If you are subject to an Involuntary Termination and you elect to continue your health insurance coverage under the
Consolidated Omnibus Budget Reconciliation Act (“COBRA”) following your Separation, then the Company will pay the same portion of your monthly premium under COBRA as it pays for active employees until the earliest of (i) the close of
the six (6) month period following your Separation, (ii) the expiration of your continuation coverage under COBRA or (iii) the date when you become eligible for substantially equivalent health insurance coverage in connection with new
employment or self-employment. 
 12. Definitions. The following terms have the meaning set forth below wherever they are used
in this letter agreement: 
 “Cause” means (a) your unauthorized use or disclosure of the Company’s
confidential information or trade secrets, which use or disclosure causes material harm to the Company, (b) your material breach of any agreement between you and the Company which you fail to correct after receiving thirty (30) days
written notification from the Chief Executive Office, (c) your material failure to comply with the Company’s written policies or rules which you fail to correct after receiving fifteen (15) days written notification from the Chief
Executive Officer, (d) your conviction of, or your plea of “guilty” or “no contest” to, a felony under the laws of the United States or any State, (e) your gross negligence or willful misconduct, (f) your
continuing failure to perform assigned duties which you fail to correct after receiving fifteen (15) days written notification of the failure from the Company’s Chief Executive Officer or (g) your failure to cooperate in good faith
with a governmental or internal investigation of the Company or its directors, officers or employees, if the Company has requested your cooperation. 

“Change in Control” means (a) the acquisition of the Company by another entity or individual or group of individuals by
means of any transaction or series of related transactions (including, without limitation, any reorganization, merger, stock purchase or consolidation) or (b) a sale of all or substantially all of the assets of the Company; unless the
Company’s stockholders of record as constituted immediately prior to any such transaction will, immediately after such transaction (by virtue of securities issued as consideration for the Company’s capital stock, assets or otherwise) hold
more than 50% of the voting power of the surviving or acquiring entity. 

 “Involuntary Termination” means either (a) your Termination Without Cause
or (b) your Resignation for Good Reason. 
 “Resignation for Good Reason” means a Separation as a result of your
resignation within twelve (12) months after one of the following conditions has come into existence without your consent: 

(a) A material diminution (greater than 10%) of your base salary; or 

(b) A material diminution of your authority, duties or responsibilities. 

(c) A requirement that you relocate more than forty (40) miles as a result of a change of the Company’s primary
location; 
 (d) Any continued material breach by the Company of its obligations under this Agreement which the Company fails
to correct after receiving fifteen (15) days written notification. 
 A Resignation for Good Reason will not be deemed to have occurred unless you give
the Company written notice of the condition within ninety (90) days after the condition comes into existence and the Company fails to remedy the condition within thirty (30) days after receiving your written notice. 

“Separation” means a “separation from service,” as defined in the regulations under Section 409A of the Code.

 “Termination Without Cause” means a Separation as a result of a termination of your employment by the Company without
Cause, provided you are willing and able to continue performing services within the meaning of Treasury Regulation 1.409A-l(n)(l). 

 The terms of this letter agreement and the resolution of any disputes as to the meaning, effect,
performance or validity of this letter agreement or arising out of, related to, or in any way connected with, this letter agreement, your employment with the Company or any other relationship between you and the Company (the “Disputes”)
will be governed by California law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in California in connection with any Dispute or any
claim related to any Dispute. 
 Except as expressly set forth above, the terms of the Employment Letter and Option Agreement shall remain
binding and in full force and effect. 
  

			
	Very truly yours,
	
	TOBIRA THERAPEUTICS, INC.
		
	By:	 	/s/ Laurent Fischer
		 	 Laurent Fischer, MD
 Chairman and Chief
Executive Officer
 Tobira Therapeutics

  

	
	ACCEPTED AND AGREED TO:
	
	/s/ Helen Jenkins
	Helen Jenkins

 Date: 29 Apr 2014

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00232-of-00352.parquet"}]]